| Deal value | $95M |
|---|---|
| Share of market cap | 32.2% |
Key highlights
- Gross proceeds of approximately $95.1 million from the second closing tranche
- Funding triggered by achievement of milestone involving FDA clearance for SZN-8141
- Expected cash runway now extends into 2029 for clinical operations
- Issuance includes 5.7 million shares and warrants for another 6.5 million shares
- Funds earmarked for DUET Phase 1b/2a study and SZN-8143 development
What Is the Capital Raise?
Surrozen finalized the second tranche of a private placement originally structured in March 2025, generating $95.1 million in gross proceeds before expenses. The closing involved the sale of 5,741,605 shares of common stock alongside pre-funded warrants for 2,456,500 shares at a purchase price of $11.60 and $11.5999 respectively. Additionally, investors received Series E common warrants to purchase approximately 4.1 million shares with an exercise price of $11.54. This financing event follows the achievement of a specific contractual milestone: the public announcement of FDA clearance for the company's Investigational New Drug application for SZN-8141 on October 2, 2026.
Use of Proceeds
- Funding the DUET Phase 1b/2a study for lead ophthalmic candidate SZN-8141
- Initiating clinical development and Phase 1b trials for the SZN-8143 program
- Extending the company’s total cash runway through the 2029 fiscal year
- Advancing the broader ophthalmology pipeline through multiple clinical milestones
- Covering placement agent fees and general corporate operating expenses
Strategic Rationale
The capital raise positions Surrozen to maintain a disciplined approach to capital allocation while pursuing aggressive clinical timelines. By tying the final tranche to the FDA's IND clearance for SZN-8141, the company successfully de-risked the investment for institutional participants while ensuring immediate liquidity upon regulatory approval. This structured approach allows the company to transition from a discovery-stage entity to a mid-stage clinical developer. The resulting balance sheet strength is intended to support the company through the delivery of initial data for the DUET study, which is currently anticipated in the second half of 2027.
Business Overview
Surrozen is a biotechnology firm specializing in the development of targeted therapeutics that harness Wnt signaling pathways. These pathways are critical for tissue repair and regeneration, specifically within the eye to address drivers of sight-threatening diseases. The lead candidate, SZN-8141, is designed as an intravitreal injection for diabetic macular edema and neovascular age-related macular degeneration. It utilizes a dual-mechanism approach, combining Frizzled 4-mediated Wnt agonism with VEGF antagonism. Beyond its lead program, the company is developing SZN-8143, another targeted Wnt agonist, aimed at restoring vascular integrity in retinal diseases where current standard-of-care treatments may be insufficient.
Financial Context
- Market capitalization stands at approximately $295.5 million following recent price action
- Reported quarterly revenue of $5.0 million with annual revenue at $3.477 million
- The company has approximately 17.8 million shares of common stock outstanding post-closing
- Previous at-the-market offerings in 2025 and 2026 raised a combined $100 million
- Current Relative Strength Index of 50.6 indicates neutral trading momentum
Up 28.6% since our story on 20 Oct: $25.14 when we broke it → $32.32 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $23.84 |
|---|---|
| 20 Oct | $25.14 |
| 21 Oct | $25.32 |
| 22 Oct | $25.75 |
| 23 Oct | $25.48 |
| 26 Oct | $27.28 |
| 27 Oct | $29.53 |
| 28 Oct | $30.35 |
| 29 Oct | $29.46 |
| 30 Oct | $29.04 |
| 2 Nov | $29.02 |
| 3 Nov | $30.12 |
| 4 Nov | $31.65 |
| 5 Nov | $29.00 |
| 6 Nov | $31.00 |
| 9 Nov | $32.00 |
| 10 Nov | $32.64 |
| 11 Nov | $31.88 |
| 12 Nov | $31.67 |
| 13 Nov | $31.61 |
| 16 Nov | $32.32 |
| Date | Announcement | Amount |
|---|---|---|
| 30 Mar 2026 | At-the-market common stock offeringSource: stocktitan.net | $50.0 Million |
| 29 Aug 2025 | At-the-market common stock offeringSource: contracts.justia.com | $50.0 Million |
| 24 Mar 2025 | Two-tranche private placement of common stock and warrantsSource: surrozen.com | $175.0 Million |
Management commentary
“The completion of this financing marks an important milestone for Surrozen, significantly strengthening our balance sheet and providing the resources to advance our ophthalmology pipeline through multiple important clinical milestones.”
“With expected cash runway into 2029, we are well positioned to advance SZN-8141 into the DUET Phase 1b/2a study and initiate clinical development of SZN-8143, while maintaining a disciplined approach to capital allocation.”
| Share price | $25.14 |
|---|---|
| Market cap | $295M |
| Revenue (annual) | $3M |
| 1-month price change | +51.90% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Surrozen, Inc. announcing the closing of the second tranche of its 2025 private placement.
Track Surrozen, Inc./DE live
Get the next Surrozen, Inc./DE SEC filing seconds after it lands.





